INOVIS  EVENTS

PharmaCI EUR Conference & Exhibition

• PharmaCI EUR has been rescheduled for November 5-6, 2020
• Zurich SWITZERLAND
• 19-20 March, 2020
• conference web site>

PRE-CONFERENCE WORKSHOP
Developing a Competitive Activity Framework to enhance organizational competitiveness

presented by

Harshal Kubavat
Head of Strategic Consulting, Global Pharmaceuticals & Life Sciences Group, INOVIS
   

This workshop session (with breakouts), will give participants first-hand insights from a combined 30+ years of experience in delivering strategic and tactical workshop-style solutions, using an optimal blend of established CI frameworks alongside INOVIS' in-house proprietary methodologies.

Key to this session will be addressing business needs across the lifecycle, whereby participants will:

• Develop an in-depth understanding of how a diverse range of facilitated activities (Rapid Immersion, Threat Assessment and Competitor Simulations) can help deliver strategic and competitive insights within an organization
• Appreciate the importance of leveraging the outcomes of workshops to inform and direct decision making
• Receive hands-on opportunities to apply learnings to a pharma case study in a learning environment

Using business case studies, real-life experiences and validated theory, the INOVIS team will equip you with a number of go-to techniques that can be rapidly integrated into ongoing CI Practice, whether you're a seasoned CI professional veteran, or newer to the field.

PLENARY (MORNING DAY 2)
Late Life Cycle Management (LLCM): The Strategic Value of Generic & Biosimilar CI In Life Sciences

presented by

Baljit Singh
Managing Director & Partner, INOVIS
(formerly Director Insights, Novartis Pharma AG)
   

This session will provide insights and highlight best practices to enable LLCM value and asset maximization by leveraging a number of tools unique to CI professionals. Specifically this presentation will enable you to:

• Advance your understanding of core Gx/biosimilar market dynamics and corresponding CI solutions
• Set up a best-in-industry Gx/biosimilar regulatory intelligence (RI) and CI tracking program
• Understand Gx / biosimilar product development and entry strategies
• Identify potential actions to optimize launches